Award Announcement - Research and Development Services for the research study titled “Therapeutic Effects of the PTP Inhibitor (NVG-291) on Sensorineural Hearing Loss After Precise Blastinduced Auditory Injury” Contract Number HT9425-24-C-0111
Award Notice Posted
- Solicitation number
- HT9425-24-LWR-AOA
- Agency
-
Defense Health Agency
Department of Defense
- Awarded
- to The Geneva Foundation
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HT9425-24-C-0111 Federal contract award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Jbsa Lackland, Texas 78236, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency awarded a $561,042 contract to The Geneva Foundation for a research study titled "Therapeutic Effects of the PTP Inhibitor (NVG-291) on Sensorineural Hearing Loss After Precise Blast-Induced Auditory Injury". The study aims to validate a rat model for blast-induced hearing injury and investigate the effects of the drug NVG-291 in mitigating sensorineural hearing damage. An unsolicited proposal from The Geneva Foundation was favorably evaluated, and market research did not identify any other sources capable of providing the required unique and innovative research services.
Notice text
Award Announcement for "Therapeutic Effects of the PTP Inhibitor (NVG-291) on Sensorineural Hearing Loss After Precise Blast-Induced Auditory Injury”. See J&A.
Awarded contract HT9425-24-C-0111 to THE GENEVA FOUNDATION for 561042.00 on 2024-09-20.
Files
| File | Type | Posted |
|---|---|---|
| JA Redacted Version Redacted.pdf |
Notice history
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity